The CBD Stock Actually Profiting Every Quarter | PureK (PKAN)
PureK Holdings Corp (CVE:PKAN) (OTCMKTS:PKANF) manufactures and sells hemp-based cannabidiol (CBD) related products in the United States. Unlike large CBD stocks like Charlotte’s Web (TSE: CWEB) (OTCMKTS:CWBHF) or cbdMD (NYSEAMERICAN: YCBD) – for all their good work – PureK actually turns a profit every quarter – having positive EBITDA since 2018.
Up to this point, the company has been profitable predominantly focusing on its PureKana brand. The all-natural CBD brand is ranked top 10 in its category.
Version 2.0 of the company will see the company expand into different areas and markets using the following four pillars.
1.Continue the growth of their profitable online platform.
2. Leverage Kathy Casey’s CPG experience (10 years at Procter & Gamble and 20 years at Kellogg’s) to take the brand into non-direct consumer avenues like brick and mortar chain stores.
3. Enter into subcategories. PureK has recently made three acquisitions over the last four months to grow into additional categories. The acquisitions of Budapest, No ‘B.S.’ Skincare, and Trubrands expand PureK’s product lines into other market segments like skincare and pet wellness.
4. PureK will be looking to expand globally. With the recent completion of its novel food agreement, the company is looking to enter into the U.K., Canada, and LATAM.
Due to the legalization of cannabidiol oil in several countries such as the U.S. and Canada, its demand is growing rapidly across the world. Some forecasts have said the market can grow at a 24.3% CAGR by 2025.
“If we can get one person off of an opioid to manage their pain in a different sustainable way, then we are making difference, and I find that incredibly rewarding” – PureK CEO Kathy Casey
Watch the entire interview to learn more about all the women-ran businesses PureK have recently acquired and the stocks future growth catalysts.
Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.
Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.
Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.